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Abstract: 
Polycystic ovarian syndrome (PCOS) is defined as the presence of hyperandrogenism (clinically and/or 
biochemically) chronic anovulation in the absence of specific adrenal pituitary gland abnormality. The clinical 
features of PCOS are Hyperandrogens, Hirsutism, Acne, Obesity, Insulin resistance. The impact of these 
symptoms on a woman quality of life may be profound and can results in psychological distress that threatens 
her feminine identity. The study shows factors impacting quality of life in women. It has been measured by using 
chi-PCOSQ (Chinese PCOS Questionnaire) Likert scale.  PCOS quality of life assessment is demonstrated by 1-
7 point likert scale. Amongst all domains impairment was seen in infertility domain followed by menstrual 
irregularity, acne, and hair loss. Spontaneous abortions were found to be frequent in PCOS patients whose BMI 
range is above normal. In present study of assessing Quality of life, treatment with metformin shows effective 
results in overweight and obese patients. Clomiphene citrate and inositol are highly effective in  non-obese and  
underweight patients.  
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INTRODUCTION: 
Polycystic ovarian syndrome is the most common 
endocrine disorder in the women of reproductive 
age with a prevalence of approximately 7-10 % 
worldwide [1]. Studies of PCOS in India reported a 
prevalence of 3.7 % to 22.5 % [2,3], with 9.13% to 
36% prevalence in adolescents only[4,5]. The 
Constitution of the World Health Organization 
(WHO) defines health as ‘A state of complete 
physical, mental and social well-being not merely 
the absence of disease’. It follows that the 
measurement of health and the affects of health 
care must include not only an indication of changes 
in the frequency and severity of diseases but also 
an estimation of wellbeing and this can be assessed 
by measuring the improvement in the quality of life 
related to health care [6,7]. The impact of these 
symptoms on a woman’s quality of life may be 
profound and it indirectly results in psychological 
distress that threatens her feminine identity. The 
condition may therefore result in altered self-
perception, a dysfunctional family dynamics and 
problems at work. The therapy of PCOS is usually 
focused on ameliorating its symptoms. Effective 
treatments in PCOS reduce the burden of these 
symptoms as well as the associated psychological 
distress and thus improve health-related quality of 
life [8-10]. Assessing HRQoL helps healthcare 
provider understand whether patients are satisfied 
with their health and associated treatments. HRQoL 
is important to consider while evaluating various 
symptom management plans and disease treatment 
[11,12], especially when they provide similar 
effects on life expectancy. According to U.S. Food 
and Drug Administration’s guidance for industry, 
assessment of HRQoL improves the clinical 
outcome and efficiency of treatment [13]. 
PCOS is a most common endocrine disorder 
affecting women of reproductive age. The 
symptoms typically associated with polycystic 
ovary syndrome (PCOS) are Acne, Hirsutism, 
Irregular menses, Amenorrhoea, Obesity and 
Infertility, a major source of Psychological 
morbidity and it shows negative impact on QoL 
[14]. Clinical features in PCOS are Reproductive 
features such as Hyperandrogenism, Hirsutism, 
Ovulatory and Menstrual dysfunction, Infertility, 
Complications in Pregnancy, Miscarriage, 
Pregnancy-Induced Diabetes (Gestational 
diabetes), Pregnancy-induced Hypertensive 
disorders and Neonatal complications and 
increased endometrial hyperplasia. Metabolic 
features such as Insulin resistance, metabolic 
syndrome, Dyslipidemia, High rates of premature 
impaired glucose tolerance, type 2 diabetes and 
increased cardiovascular risk factors. Psychological 
features such as anxiety, depression, poor self-
esteem, reduced quality of life and negative body 
image are observed [15]. 
 
Fig:1 Schematic Representation of Etiology and 
Clinical features of PCOS [16]  
The Hyperinsulinemia appears to be an important 
factor in maintaining hyperandrogenemia, acting 
directly to induce excess androgen production by 
theca cells leading to anovulation[17]. Obesity does 
in fact have profound effects on both 
pathophysiology and the clinical manifestation of 
PCOS by different mechanisms leading to 
androgen excess and increased free androgen 
availability affects the alterations of granulosa cell 
function and follicle development [18]. 
Clomiphene citrate remains the treatment of first 
choice for induction of ovulation in anovulatory 
women with PCOS. The staring dose of 
Clomiphene citrate is 50 mg/day (for 5 days) and 
the recommended maximum dose is 150 
mg/day[19]. Clomiphene citrate act as an anti-
oestrogen, inhibits the binding of estradiol to its 
receptors in the hypothalamus and pituitary which 
inturn blocks the negative feedback effect of 
endogenous estrogens including estradiol [20] .  
Metformin is taken in a dose that the woman can 
tolerate. The most effective dose for PCOS is 
generally 500 mg 3 times daily. Metformin reduces 
the insulin response by decreasing hepatic 
gluconeogenesis and reducing androgen levels 
[21]. Inositol molecule also reduces insulin 
resistance, improve ovarian function, and reduce 
androgen levels in women with PCOS [22]. 
Polycystic ovarian syndrome questionnaire is a 
disease specific HRQOL questionnaire that 
contains six domains. The questionnaire was taken 
from chi-PCOSQ. 
DOMAINS: Each domain has its related questions 
such as emotional (7), Weight (6), Body hair (5), 
Infertility problems (3), Acne and hair loss (5), 
Menstrual problems (5). The first domain has a 
question which helps to assess the psychometric 
properties of the patients. It is calculated by 7 point 
scale (1: indicates maximum impairment and 7 
indicates no impairment of HRQOL). 
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1-7 Point  likert scale  scoring :  
Options are explained below based on this criteria 
scoring has been given. 
1- All of the time,  2-Most of the time,  3-A Good 
Bit of the time, 4-Some of the time,  
5- A little of the time, 6-Hardly any of the time, 7-
None of the time. 
The average (mean) of domain shows the impact of 
each domain in the patient.  
EMOTIONAL DOMAIN - The importance of 
this domain is to estimate the condition of the 
patient based on their emotions (depression, 
anxiety and low esteem) which consists of 
questions regarding low self-esteem, mood swings, 
and lack of control over the situation with PCOS. 
The average of the domain indicates the patient’s 
emotional status. 
WEIGHT DOMAIN - Obesity plays a major role 
in PCOS. Obesity is a symptom and a risk factor 
for poly cystic ovarian syndrome. It also shows 
affect on insulin and it leads to insulin resistance. 
The domain indicates questions like the experience 
with difficulties staying at ideal weight, concern 
about being over-weight, frustration in trying to 
lose weight, trouble in managing weight. The 
domain average shows the impact of weight 
changes in patient’s life.  
BODY HAIR - Hirsutism is one of the clinical 
features in PCOS. It may not occur in all the 
patients but it affects the patients who are with 
increased androgen level in the body. The domain 
implies the patients who are suffering with 
embarrassment about excessive body hair, growth 
of visible body hair, hair on face, hair on upper lip 
and chin. These symptoms may affect the patient 
psychologically which indirectly affects the quality 
of life. 
INFERTILITY PROBLEMS - Anovulation is 
common in PCOS patients which results in the 
concern about infertility problems. The domain 
average indicates impact on QoL. 
ACNE AND HAIR LOSS - Patient may 
experience acne and may have excess hair loss due 
to hyperandrogenism. This affects the patients 
physiologically and psychologically. The domain 
average indicates impact of acne and hair loss in 
patient’s quality of life. 
MENSTRUAL PROBLEMS - Menstrual 
irregularity is a major clinical feature in PCOS. The 
domain average indicates the patients suffering 
during menstruation like abdominal bloating, 
menstrual cramps, last menstruation period and 
irregular menstrual periods. 
 
MATERIALS AND METHODS: 
STUDY SITE:  
A prospective observational study was conducted 
at a Infertility center in Warangal. Patients were 
selected based on inclusion criteria and filled 
questionnaires were collected from patients.  
STUDY DESIGN: It is a Prospective 
observational study. 
STUDY PERIOD: This study has been carried out 
for 6 months period. 
STUDY CRITERIA: All participants were 
provided written informed consent regarding their 
willingness to participate in the study. Patients who 
signed informed consent were included in the 
study. 
INCLUSION CRITERIA: 
Patients diagnosed with PCOS [Outpatients] 
Patients of reproductive age group. 
Patients able to respond to the questionnaire. 
Patients who are regularly visiting to the clinic.  
EXCLUSION CRITERIA: 
Patients who are not diagnosed with PCOS. 
Patients diagnosed with similar clinical 
presentation including congenital adrenal 
hyperplasia, androgen secreting tumors, Cushing’s 
syndrome, thyroid dysfunction and 
hyperprolactinaemia.  
Patients who are not willing to participate in the 
study and patients who have other infertility 
problems. 
SOURCE OF THE DATA: Direct 
communication with patients and care takers and 
review of patient records. Demographics and other 
pertinent clinical data was collected from the 
patients along with filled questionnaires. 
All our the study patients filled questionnaire but 
follow up was taken from 42 patients and their 
ovulation data, medication regimen (Metformin 
500mg; Myo-inositol 550mg; Clomiphene citrate 
50mg to 100mg) was analyzed based on ovulatory 
cycles and number of ovulations.  
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CHINESE POLYCYSTIC OVARIAN SYNDROME QUESTIONNAIRE PRODUCED WITH PERMISSION 
[Huang et al] [23]. 
DOMAINS 
EMOTIONS: 
Q11 Low self-esteem as a result of PCOS 
Q18 Self-conscious as a result of having PCOS 
Q6  Moody as a result of having PCOS 
Q2 Depressed as a result of having PCOS 
Q17 Worried about having PCOS 
Q14  Afraid of getting cancer 
Q23 Lack of control over the situation with PCOS 
WEIGHT 
Q24 Difficulties staying at your ideal weight 
Q3  Concerned about being over weight 
Q12 Frustration in trying to lose weight 
Q10 Trouble dealing with weight 
Q22 Feel unsexy because overweight 
Q14   Afraid of getting diabetes 
BODY HAIR: 
Q16   Embarrassment about excessive body hair 
 Q26 Growth of visible body hair 
 Q15 Growth of visible hair on your face 
 Q9  Growth of visible hair on upper lip 
 Q1 Growth of visible hair on chin 
INFERTILITY 
Q5 Concerned about infertility problems 
Q25 Sad because of infertility problems 
Q13 Afraid of not being able to have children 
ACNE AND HAIR LOSS 
Q29 Growth of visible acne 
Q30 Feel acne is a problem 
Q27 Excess hair loss 
Q28  Feel excess hair loss is a problem 
Q4 Tired easily 
MENSTRUAL 
Q19 Abdominal bloating 
Q21 Menstrual cramps 
Q20 Last menstruation period 
Q8 Irregular menstrual periods 
Q7 Headaches 
 
RESULTS AND DISCUSSION: 
Present study measures the psychological and 
emotional status of the patients. The each domain 
in PCOS indicates the patient’s quality of life. As 
successful treatment of PCOS reduce the burden of 
the symptoms and as associated psychosocial stress 
[24] has an important impact on woman’s HRQOL, 
assessment of HRQOL plays a vital role to evaluate 
the effectiveness in PCOS [25].The symptoms 
typically associated with PCOS are Amenorrhea, 
oligomenorrhea, hirsutism, obesity, infertility, 
anovulation and acne these lead to reduction of 
HRQoL which shows impact on emotional 
wellbeing. 
 
 
 
 
 
IAJPS 2017, 4 (10), 3430-3438                      P.Kishore et al                         ISSN 2349-7750 
 
 
 w w w . i a j p s . c o m  
 
Page 3434 
 
 
 
 
 
 
 
 
 
 
 
Fig 2:   Percentage of distribution of patients according to their BMI 
 
In the present study 240 patient data was assessed. 
The average BMI in the study group is 60.18 ± 
11.84 more than half of the women (n=133; 
55.41%) had normal body weight [BMI: 19-25], 
and 30% [n=70] of the patients were in class I 
(BMI: 30-34.9); 11% [n=26] of the patients were 
class-II obese (BMI-35.0-39.9) followed by 4.5% 
[n=11] with underweight. Similarly a study 
conducted by stadnicka et al [28] reveals that the 
average BMI (body mass index) of 24.68±4.52 and 
over half [n=46, 59%] of the examined women had 
normal BMI, 1 in 4 respondents (21; 26.92%) had 
overweight (BMI 26-30), and 1 in 10 (14.11%) 
were obese (BMI>30) [28] . Due to obesity and 
increased androgens levels, decreased Sex hormone 
binding globulin levels were seen. This is one of 
the causes for PCOS. Majority of the patients in 
our study had normal Body Mass Index which is 
similar to the study of stadnicka et al [28] 
Counseling had positive impact on the patients 
leading to significant weight reduction and 
follicular improvement. 
 
Fig 3: Percentage of patients with menstrual irregularities 
In present study, 26.66 % patients were suffering with Dysmenorrhea followed by Oligomenorrhea (15%) (n-
38), Menorrhagia 9% (n-21), Polymenorrhea 7% (n-16), Amenorrhea 3% (n-5), Bleeding with clots 17% (n-40) 
and 24.16 % of patients are regular menstruation with the use of medication. 
 
F
ig 4: Gravida history in PCOS patients 
In present study out of 240 patients 71.25 % (n-171) patients never had pregnancy, 29 % (n-69) of patients had 
history of terminations.    
4.5%
55.41%
29.16%
10.83%
under weight (<18.5 kg/m²)
Normal  (18.5-24.9kg/m²)
obesityclass 1  (25.0-
29.9kg/m²)
obesity Class II (30.0-
34.9kg/m²)
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Fig 5: History of abortions in PCOS patients 
 
Fig 6: Average score of all domains in the questionnaire 
 
In present study fig 5 shows 29 % (n-69) of 
subjects had history of pregnancy and in which 
4.58 %(n-11) success rate of  pregnancy was 
observed, 3.33% (n-8) had termination history 
(Due to consanguineous marriage),12.5 %(n-30) of 
them <1 termination and 8.33% (n-20) of subjects 
with >1 which is similarly to the study Fatemeh 
Bazarganipour et al [26]. A spontaneous 
termination in patients with BMI above 30.0-
34.9kg/m² was observed which is similar to study 
Jim X.Wang et al [26]. The concentration of 
estradiol at oocyte retrieval was also positively 
associated with the risk of miscarriage similar to 
the study Jim X.Wang et al [27]. 
 
In figure 6 shows the maximum impairment was 
seen in infertility domain 3.201 followed remaining 
domains. Mean scores of chi PCOSQ’s sub scales 
in PCOS patients 1: indicates maximum 
impairment and 7: indicates no impairment. 
In our study, the maximum impairment was seen in 
infertility domain among all the domains. The 
mean of infertility domain is 3.20. It shows 
negative impact on patient’s quality of life. Similar 
study by Stadnika G et al [28] shows that infertility 
domain mean score was 4.33 which is second 
highest concern on the PCOSQ. No regular cycle 
and sometimes even no menstrual bleeding without 
the use of medication are strongly related with 
infertility and because of this the patients rated 
their infertility as a bigger problem. However, 
some socio cultural generalizations are possible. 
The social pressure to have a child shortly after 
marriage is strong. Similar to the study Joshi B et 
al [3] social pressure for infertility shows a 
negative impact Quality of life of patients. 
Menstrual irregularities are the major clinical 
feature in PCOS. The mean of the menstrual 
domain is 3.679; it shows major impact on the 
quality of life of PCOS patients. Mean value 
indicates the ‘moderate problem’ towards 
menstrual cycle and some of them had regular 
menstrual cycle with the use of medications. This 
may be the reason for the decrease in clinical 
presentation [amenorrhea, menorrhagia, 
oligomenorrhea, and dysmenorrhea] in the PCOS 
patients using medications. The physical stress 
results in hormonal imbalance which leads to 
anovulation in the PCOS women. Similarly a study 
reported that the menstrual domain had most 
negative influence on HRQoL, because the 
majority of participants had oligomenorrhea, 
amenorrhea similar to the conducted by Stadnika G 
et al [28]. 
Acne and hair loss is a clinical representation for 
increased testosterone levels and hormonal 
imbalance. Majority of the patients were suffering 
with acne and hair loss. The mean of acne and hair 
loss domain is 3.69. This domain stands as the third 
most effecting domain in Chi-PCOSQ. The 
4.188 4.112 4.367
3.201
3.679 3.693
Emotions weight body hair Infertility menstrual acne & hair loss
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physical appearance of the patients [acne and hair 
loss] is significantly affecting the patient’s quality 
of life. 
In the weight domain, the mean score is 4.112 
Similar to the study of Stadnika et al[28]. Obesity 
shows negative impact on HRQoL in PCOS 
women. An increased cholesterol level in obese 
women affects the Sex hormone binding globulin 
significantly which leads to hormonal imbalance. 
In present study mean value of body hair domain 
4.367 which shows the majority of the patients 
were suffering with hirsutism. Comparing with the 
study of Fatemeh Bazarganipour et al [26] shows 
similar significant values of emotional 4.188 and 
body hair domain 4.367 were found. Women with 
PCOS have lower self-esteem, more negative self-
image, higher levels of depression and 
psychological distress owing to the increased levels 
of androgens similar to the study of Fatemeh 
Bazarganipour et al [26].  
 
Fig 7: BMI vs drugs used in the treatment of PCOS 
          
 
Fig 8: Comparision of follicular size before treatment and after treatment 
 
 
Metformin showed in fig 7 effective results in the 
overweight and obese patients. Clomiphene citrate, 
inositol are highly effective in non-obese as well as 
in underweight patients. Drug efficacy and number 
of ovulations were differentiated based on their 
BMI ranges similarly to the study of Mahnaz 
Ashrafi  et al[29].      
 
In figure 8, Increase in follicular size (>18mm) was 
clearly observed in 42 patients after treatment and 
counseling, compared to before treatment (<15mm 
in 17 patients, <10mm in 25 patients). Counseling 
sessions helped patient reduce significant amount 
of weight, develop self-confidence, impart positive 
attitude, all leading to normal physiological 
follicular function. 
 
CONCLUSION: 
PCOS quality of life assessment was demonstrated 
by 1-7 point Likert scale. Arranging all domains, 
impairment was seen in infertility domain followed 
by menstrual irregularity, acne, hair loss domain, 
weight, Body hair, Emotions. The complaints of 
menstrual irregularities like oligomenorrhea, 
amenorrhea, polymenorrhea, and menorrhagia were 
subsided by medication adherence. The quality of 
81.8%
72%
66.6%
57.14%
58.33%
50%
83.33%
87.5%
obese(n-10)
over weigh(n-11)
non -obese(n-16)
under weight(n-5)
metformin clomiphene inositol
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life was seen to be affected by severe acne, hair 
loss and hirsutism in patients leading to low 
emotional quotient. Metformin showed effective 
results in the overweight and obese patients. 
Clomiphene citrate, inositol are highly effective in 
non-obese as well as in underweight patients. 
Counseling sessions help to improve the patient’s 
psychological and physiological health status. 
Spontaneous abortions were found to be frequent in 
PCOS patients whose BMI range is above normal. 
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